Quarterly Earnings

The asset manager closed 2025 with massive assets, but significant Q4 client withdrawals raise questions about strategy ahead of its earnings call.

Vericel posts strong 2025 results driven by its MACI cartilage therapy. The biotech leader is now investing in a new facility and a clinical trial for ankle repair.

Amid market pressures, VirTra showcases its advanced training simulators at SHOT Show, betting on immersive tech to redefine law enforcement training.

Medical device firm CVRx is under investigation after its stock nosedived. Did management mislead investors about its salesforce stability?

The high-power laser maker exceeded its Q4 guidance, driven by booming demand in aerospace and defense. Here's what it means for its 2026 outlook.

With Vans in a slump and The North Face soaring, VF Corp's new leadership will detail its strategic vision at a key conference watched by Wall Street.

The media giant posts strong Q3 results, unveiling its 'GTPL Infinity' platform to counter competition and capture India's booming digital market.

Medallion Bank promotes from within, elevating key execs to steer its strategy in the specialized RV, boat, and home improvement lending markets.

Sonos adds leaders from Meta, e.l.f. Beauty, and Pandora to its board, signaling a strategic push into AI, platform growth, and financial discipline.

Investors and HR leaders watch as Unum prepares to release its Q4 results and 2026 strategy in a rapidly evolving workplace benefits landscape.

Avalon GloboCare regains Nasdaq compliance, but its future is being reshaped by a bold AI launch and a transformative merger that questions its identity.

Progyny signals better-than-expected 2025 results on robust member engagement, sparking analyst upgrades and sending its stock soaring ahead of a key conference.

As McGraw Hill execs prep for a key investor conference, all eyes are on their digital-first strategy and how they'll navigate the AI-driven EdTech boom.

The wellness firm secured a cash infusion by repricing options, a move that provides vital funds for its Zola brand but raises questions about dilution.

The genomics leader posted a 41% revenue surge in 2025 and projects profitability, yet its stock tumbled on what some see as conservative 2026 guidance.

With a major strategic pivot complete, Gibraltar Industries' leadership will outline its 2026 playbook to investors at a key 'New Ideas' conference.

Adaptive posted a 55% revenue surge in 2025, fueled by its clonoSEQ cancer test. Now, the firm is charting a clear course to company-wide profitability.

BioXcel Therapeutics is pushing its drug IGALMI® for home use, a move that could transform mental healthcare but carries significant financial and safety risks.

As subsea tech leader Kraken Robotics sees explosive growth, it brings on veteran Terra Penrose as Chief People Officer to scale its global workforce.

As WD-40 leaders prepare for the ICR Conference, investors weigh strong growth plans against a recent earnings miss and a major brand overhaul.